Next Article in Journal
Mitochondrial Metabolic Reprogramming in Colorectal Cancer-Associated Fibroblasts: An Up-to-Date Review
Previous Article in Journal
Risk of Malignancy with Immunosuppressive Drugs Used in Organ Transplants Compared to Those Used for Non-Transplant Indications
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 18
Issue 11
10.3390/cancers18111785
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Cancers 2026, 18(2), 181.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Salakphet et al. Molecular Classification and Clinical Outcomes in Endometrial Cancer: Real-World Evidence from a Tertiary Care Center. Cancers 2026, 18, 181

by
Tanadon Salakphet
1,
Prapaporn Suprasert
1,*,
Tip Pongsuvareeyakul
2,
Chinachote Teerapakpinyo
3 and
Surapan Khunamornpong
2
1
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
2
Division of Gynecologic Pathology, Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
3
Chula GenePRO Center, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
*
Author to whom correspondence should be addressed.
Cancers 2026, 18(11), 1785; https://doi.org/10.3390/cancers18111785
Submission received: 28 April 2026 / Accepted: 26 May 2026 / Published: 29 May 2026
Versions Notes
Error in Table
In the original publication [1], there was a mistake in Table 2 as published. The final line of Table 2 was omitted. The corrected Table 2 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Salakphet, T.; Suprasert, P.; Pongsuvareeyakul, T.; Teerapakpinyo, C.; Khunamornpong, S. Molecular Classification and Clinical Outcomes in Endometrial Cancer: Real-World Evidence from a Tertiary Care Center. Cancers 2026, 18, 181. [Google Scholar] [CrossRef] [PubMed]
Table 2. Univariate and Multivariate Logistic Regression Analysis of Clinicopathological Factors Associated with MMR and p53 Status.
Table 2. Univariate and Multivariate Logistic Regression Analysis of Clinicopathological Factors Associated with MMR and p53 Status.
FactorsMMRp53
dMMR (%)pMMR (%)TotalUnadjusted OR *
(95%CI)		p ValueAdjusted OR **
(95%CI)		p ValueWildAbnormalTotalUnadjusted OR *
(95%CI)		p ValueAdjusted OR **
(95%CI)		p Value
Age (years)
≤60 years52 (81.3)12 (18.8)64 (63.4)3.683
(1.496–9.070)		0.0062.611
(0.888–7.677)		0.08133 (61.1)21 (38.9)54 (40.6)5.731
(2.663–12.332)		<0.0017.952
(1.208–47.697)		0.031
>60 years20 (54.1)17 (45.9)37 (36.6)17 (21.5)62 (78.5)79 (59.4)
BMI
<2547 (75.8)15 (24.2)62 (61.4)1.755
(0.731–4.210)		0.260--32 (43.8)41 (56.2)73 (54.9)1.821
(0.886–3.742)		0.109--
≥2525 (64.1)14 (35.9)39 (38.6)18 (30.0)42 (70.0)60 (45.1)
UD
None28 (82.4)6 (17.6)34 (33.7)2.439
(0.883–6.736)		0.104--25 (67.6)12 (32.4) 5.917
(2.519–13.509)		<0.0015.618
(0.870–36.278)		0.070
Present44 (65.7)23 (34.3)67 (66.3)25 (26.0)71 (74.0)
Residual disease
None65 (70.7)27 (29.3)92 (91.1)0.688
(0.134–2.526)		0.727--45 (37.5)75 (62.5)120 (90.2)0.960
(0.269–3.114)		1.000--
Present7 (77.8)2 (22.2)9 (8.9)5 (38.5)8 (61.5)13 (9.8)
Histology
Endometrioid65 (86.7)10 (13.3)75 (74.3)17.463
(5.915–52.622)		<0.00115.215
(4.992–46.374)		<0.00146 (80.7)11 (19.3)57 (42.9)75.273
(22.611–250.586		<0.00179.416
(10.599–595.049)		<0.001
Non-endometrioid7 (26.9)19 (65.5)26 (25.7)4 (5.3)72 (94.7)76 (57.1)
MI
Less than 50%39 (76.5)12 (23.5)51 (50.5)1.674
(0.700–4.006)		0.277-- 1.266
(0.625–2.563)		0.590--
≥50%33 (66.0)17 (28.7)50 (49.5)26 (35.1)48 (64.9)74 (55.6)
LVSI
None45 (73.8)16 (26.2)61 (60.4)1.354
(0.565–3.244)		0.509-- 0.627
(0.309–1.275)		0.210--
Present27 (67.5)13 (32.5)40 (39.6)25 (50.0)32 (56.1)57 (42.9)
Peritoneal cytology
Negative70 (72.9)26 (27.1)96 (95.0)4.038
(0.638–25.555)		0.141--48 (40.7)70 (59.3)118 (88.7)4.457
(0.962–20.653)		0.050--
Positive2 (40.0)3 (60.0)5 (5.0)2 (13.3)13 (86.7)15 (11.3)
Stage ***
I&II47 (78.3)13 (21.7)60 (59.4)2.314
(0.962–5.568)		0.074--33 (44.0)42 (56.0)75 (56.4)1.895
(0.917–3.918)		0.105--
III&IV25 (61.0)16 (39.0)41 (40.6)17 (29.3)41 (70.7)58 (43.6)
Risk
Low&intermediate44 (89.8)5 (10.2)49 (48.5)7.543
(2.578–22.072)		<0.0011.329
(0.298–5.919)		0.70931 (81.6)7 (18.4)38 (28.6)17.714
(6.769–46.357)		<0.0011.848
(0.059–57.817)		0.727
High risk28 (53.8)24 (46.2)52 (51.5)19 (20.0)76 (80.0)95 (71.4)
Adjuvant RT
None31 (77.5)9 (22.5)40 (75.5)0.287
(0.03–2.516)		0.419--19 (32.2)40 (67.8)59 (84.3)0.048
(0.006–0.398)		<0.0010.268
(0.020–3.600)		0.320
Present12 (92.3)1 (7.7)13 (24.5)10 (90.9)1 (9.1)11 (15.7)
Adjuvant CT
None66 (74.2)23 (25.8)89 (88.1)2.870
(0.841–9.789)		0.098--44 (44.9)54 (55.1)98 (73.7)3.938
(1.500–10.337)		0.0040.546
(0.037–8.013)		0.659
Present6 (50.0)6 (50.0)12 (11.9)6 (17.1)29 (82.9)35 (26.3)
* Chi-square or Fisher’s exact test. ** Binary regression (Backward, likelihood ratio). *** Figo stage 2018. MMR, mismatch repair gene; dMMR, deficient mismatch repair; pMMR, proficient mismatch repair; OR, odds ratio; CI, confidence interval; BMI, body mass index; UD, underlying disease; MI, myometrial invasion; LVSI, lymphovascular space invasion; RT, radiation therapy; CT, chemotherapy.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Salakphet, T.; Suprasert, P.; Pongsuvareeyakul, T.; Teerapakpinyo, C.; Khunamornpong, S. Correction: Salakphet et al. Molecular Classification and Clinical Outcomes in Endometrial Cancer: Real-World Evidence from a Tertiary Care Center. Cancers 2026, 18, 181. Cancers 2026, 18, 1785. https://doi.org/10.3390/cancers18111785

AMA Style

Salakphet T, Suprasert P, Pongsuvareeyakul T, Teerapakpinyo C, Khunamornpong S. Correction: Salakphet et al. Molecular Classification and Clinical Outcomes in Endometrial Cancer: Real-World Evidence from a Tertiary Care Center. Cancers 2026, 18, 181. Cancers. 2026; 18(11):1785. https://doi.org/10.3390/cancers18111785

Chicago/Turabian Style

Salakphet, Tanadon, Prapaporn Suprasert, Tip Pongsuvareeyakul, Chinachote Teerapakpinyo, and Surapan Khunamornpong. 2026. "Correction: Salakphet et al. Molecular Classification and Clinical Outcomes in Endometrial Cancer: Real-World Evidence from a Tertiary Care Center. Cancers 2026, 18, 181" Cancers 18, no. 11: 1785. https://doi.org/10.3390/cancers18111785

APA Style

Salakphet, T., Suprasert, P., Pongsuvareeyakul, T., Teerapakpinyo, C., & Khunamornpong, S. (2026). Correction: Salakphet et al. Molecular Classification and Clinical Outcomes in Endometrial Cancer: Real-World Evidence from a Tertiary Care Center. Cancers 2026, 18, 181. Cancers, 18(11), 1785. https://doi.org/10.3390/cancers18111785

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop